Diltiazem Treatment for Preclinical Hypertrophic Cardiomyopathy Mutation Carriers: A Pilot Randomized Trial to Modify Disease Expression

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by sarcomere mutations and characterized by left ventricular hypertrophy (LVH) with increased risk of heart failure and sudden death. HCM typically cannot be diagnosed early in life, although subtle phenotypes are present. Animal studies indica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JACC Heart Fail
Asıl Yazarlar: Ho, Carolyn Y., Lakdawala, Neal K., Cirino, Allison L., Lipshultz, Steven E., Sparks, Elizabeth, Abbasi, Siddique A., Kwong, Raymond Y., Antman, Elliott M., Semsarian, Christopher, González, Arantxa, López, Begoña, Diez, Javier, Orav, E. John, Colan, Steven D., Seidman, Christine E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4323670/
https://ncbi.nlm.nih.gov/pubmed/25543971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2014.08.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller